Drug intelligence / Profile preview

SPWCV + alum

Development stage: Unknown
Lead developer: PATH Vaccine Solutions
Modality: Recombinant Proteins and Enzymes, Liposomes → Lipid-based Nanoparticles → Nanoparticles → Drug Delivery Systems, Vaccines & Immunotherapeutics
Administration: Intramuscular

Overview

SPWCV + alum is a combination vaccine candidate composed of the SARS-CoV-2 spike protein subunit vaccine (SPWCV) formulated with aluminum-based adjuvant (alum). The SPWCV component is a recombinant protein subunit designed to elicit an immune response against the spike protein of SARS-CoV-2, the virus responsible for COVID-19. Alum serves as an adjuvant to enhance immunogenicity by promoting stronger and longer-lasting antibody responses. This combination is being developed as a prophylactic vaccine for COVID-19.

Targets

RBD (SARS-CoV-2 spike receptor-binding domain)

Beyond the preview

Go deeper on SPWCV + alum.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on SPWCV + alum.

Explore the full profile